Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, is a leading global pharmaceutical company dedicated to discovering, developing, and marketing innovative medicines in the fields of neurology and oncology. Guided by its corporate philosophy of “giving first thought to patients and their families,” Eisai has built a reputation for research-driven drug development and patient-focused healthcare solutions over more than seven decades.
Eisai’s product portfolio spans treatments for Alzheimer’s disease, cancer, epilepsy, and sleep disorders. Its flagship Alzheimer’s therapy, donepezil (marketed as Aricept), remains a cornerstone in managing cognitive symptoms. In oncology, Eisai developed lenvatinib (Lenvima) for thyroid, liver, and renal cancers, and continues to advance targeted therapies in collaboration with global partners. Additional products address neurological conditions ranging from epilepsy to insomnia, reflecting the company’s ongoing commitment to brain health.
With operations in over 20 countries, Eisai maintains research and development sites in Japan, the United States, Europe, and Asia to support its worldwide clinical programs. The company leverages strategic alliances with other biopharmaceutical firms and academic institutions, most notably its collaboration with Biogen on antibody-based approaches for Alzheimer’s disease. This extensive network enables Eisai to accelerate clinical trials, regulatory approvals, and market access across diverse regions.
Under the leadership of President and CEO Haruo Naito, Eisai emphasizes patient-centric innovation and sustainable growth. The company allocates significant resources to next-generation modalities such as antibody-drug conjugates, immunotherapies, and precision medicine. By combining scientific expertise with a strong commitment to patient welfare, Eisai aims to address unmet medical needs and expand its impact in therapeutic areas characterized by high global demand.
AI Generated. May Contain Errors.
